G1 Therapeutics, Inc.
Combination therapy for treatment of cancer
Last updated:
Abstract:
Compositions, combinations and methods comprising a CDK4/6 inhibitor of Formula D with a selective estrogen receptor downregulator of Formula A, B or C that are advantageous for the treatment of abnormal cellular proliferation, including a cancer or a tumor.
Status:
Grant
Type:
Utility
Filling date:
2 Jul 2019
Issue date:
21 Jun 2022